Header Logo

Connection

Ruiwen Zhang to Antineoplastic Agents

This is a "connection" page, showing publications Ruiwen Zhang has written about Antineoplastic Agents.
Connection Strength

3.647
  1. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacol Rev. 2024 May 02; 76(3):414-453.
    View in: PubMed
    Score: 0.822
  2. Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. Cancer Lett. 2021 01 01; 496:16-29.
    View in: PubMed
    Score: 0.641
  3. Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy. Cells. 2020 05 09; 9(5).
    View in: PubMed
    Score: 0.624
  4. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Res. 2018 10 01; 78(19):5656-5667.
    View in: PubMed
    Score: 0.556
  5. Preface. Curr Cancer Drug Targets. 2018; 18(1):2.
    View in: PubMed
    Score: 0.530
  6. Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. Eur J Med Chem. 2021 Jan 01; 209:112866.
    View in: PubMed
    Score: 0.160
  7. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells. 2020 Jul 01; 9(7).
    View in: PubMed
    Score: 0.157
  8. JP1 suppresses proliferation and metastasis of melanoma through MEK1/2 mediated NEDD4L-SP1-Integrin avß3 signaling. Theranostics. 2020; 10(18):8036-8050.
    View in: PubMed
    Score: 0.157
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.